Aché Laboratórios migrates to HANA
FH customer is featured in Baguete, the largest IT portal in Brazil.
Aché Laboratórios is one of the largest companies in the Brazilian pharmaceutical industry that migrated part of its Oracle databases to the HANA platform in memory as part of a recent upgrade to the company’s SAP management systems.
The project involves Aché and Biosintética as well as the subsidiaries Magenta, Mafra and Propecus. The work lasted four months and was completed in February 2016, involving about 100 people and five service companies including SAP itself for the technical area of HANA and FH for the functional part.
“It’s clear that Hana will be the foundation of SAP’s strategy for the next few years. We want to align our digital transformation efforts with the latest in the market, “said Eduardo Kondo, Aché’s Information Technology Manager.
The company has already adopted some modules of SAP systems designed to run exclusively on HANA, the so-called S/4 generation, including a production planning and budget planning.
“We are developing solutions that will integrate expert information and consumer experiences into a unified digital platform, facilitating the flow of information, contributing to prevention and treatment,” explains Kondo.
The idea is to keep adding the latest versions of SAP technology in the coming months. According to Kondo, on processed data volumes Aché infra now divides me 20% with HANA and another 40% for legacy systems running on Oracle and SQL Server.
The migration to HANA reduced hardware licensing costs by 3%, while at the same time greatly accelerated some workflows. The extraction of invoices for the transport composition, which used to last for about 30 minutes, now takes less than one minute.
“Other benefits are in a few steps within the accounting closing process, reduced from 10 minutes to an instant and online processing. The project will bring performance gains, making some processes up to 10 times faster”, says Leandro Roldão, Manager of Information Systems at Aché.
Aché has no sense in the effects of the crisis. The company plans to invest R$ 80 million in 2016 in the expansion of its operations, with factories in Guarulhos, Santo Amaro, Anápolis and an operation recently acquired in Londrina.
Between January and September of last year, the company had total sales of R $ 3.18 billion, up 22% from the previous year, totaling about 5.6% of the national market, according to a study by Exame.
It’s an above-average performance. In the same period, the pharmaceutical sector grew 15.01%. The data are from a survey of IMS Health consultancy, made at the request of the Brazilian Association of Generic Medicines Industries (PróGenéricos).
Source (content in Portuguese): Maurício Renner – Baguete
